Big effect
IV iron cut heart failure hospitalizations and cardiovascular death by 21% in a meta-analysis — but only in patients with chronic kidney disease.
This is a promising signal for a specific, high-risk group, but the finding comes from only a handful of studies and needs replication before it changes practice.
In a meta-analysis of 7,009 patients with heart failure and chronic kidney disease, intravenous iron therapy reduced the risk of a first heart failure hospitalization or cardiovascular death by 21% (RR 0.79). However, the same treatment did not significantly lower all-cause mortality, meaning the benefit appears limited to that combined endpoint. Because this is among the first large analyses of this specific pairing, the results should be viewed as preliminary rather than definitive.
Where this fits in the evidence
This is among the first studies we've indexed on Iron for Reduced First Heart Failure Hospitalization or Cardiovascular Death — treat it as an early signal until more research accumulates.
The study
- Meta-Analysis
- n = 7,009
- 2026-03-27
- BMC cardiovascular disorders
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.